title: Effect of estradiol 17beta upon coronary artery vasoconstrictor response to methylergometrine maleate in female menopausal patients.
abstract: BACKGROUND
  Estrogens produce several beneficial effects upon the cardiovascular system. Amongst these, an endothelium-independent effect has been convincingly demonstrated only in vitro, while there is no evidence for such an effect in vivo. The aim of the present study was to evaluate the effect of acute administration of estradiol 17beta upon coronary artery reactivity to methylergometrine in 16 menopausal patients with coronary artery disease.
  
  
  METHODS
  Sixteen menopausal patients underwent coronary angiography at rest and after incremental doses of methylergometrine (intracoronary 2, 10, 30 microg) before and 20 min after either intracoronary estradiol 17beta (20 ng/mL at 1 mL/min for 20 min; 8 patients) or placebo (Dextrose 5%, 1 mL/min; 8 patients).
  
  
  CONCLUSIONS
  No significant differences were observed in baseline coronary artery diameter or area between the 2 groups. No significant differences in the degree of coronary artery constriction were observed after either estradiol 17beta or placebo at submaximal doses of methylergometrine. However, the degree of coronary artery constriction after maximal doses of methylergometrine was significantly attenuated by estradiol 17beta compared to placebo (change in diameter: -0.9+/-4.5% vs. -19+/-6%, p<0.001; change in area: -3.2+/-9% vs. -32.2+/-10%, p<0.001). Estradiol 17beta reduces coronary artery constriction following methylergometrine administration in menopausal patients with coronary artery disease. This effect may be related to the calcium-antagonist properties of the ovarian hormone.
authors.affiliation: Department of Medical Sciences, IRCCS San Raffaele Hospital, Tosinvest Sanità, via della Pisana 235, 00164 Roma, Italy. giuseppe.rosano@sanraffaele.it
authors.forename: Giuseppe M C
authors.initials: GM
authors.lastname: Rosano
authors.forename: Peter
authors.initials: P
authors.lastname: Collins
authors.forename: Otavio
authors.initials: O
authors.lastname: Gerbara
authors.forename: Imad
authors.initials: I
authors.lastname: Sheiban
authors.forename: Antonello
authors.initials: A
authors.lastname: Silvestri
authors.forename: Mauricio
authors.initials: M
authors.lastname: Wajngarten
authors.forename: Josè A
authors.initials: JA
authors.lastname: Ramires
authors.forename: Massimo
authors.initials: M
authors.lastname: Fini
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Mercuro
mesh_terms: D000368:Aged; D016022:Case-Control Studies; D017023:Coronary Angiography; D003324:Coronary Artery Disease / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000503:physiopathology; D003331:Coronary Vessels / Q000187:drug effects* / Q000503:physiopathology; D004305:Dose-Response Relationship, Drug; D004730:Endothelium, Vascular / Q000187:drug effects / Q000503:physiopathology; D004958:Estradiol / Q000008:administration & dosage / Q000494:pharmacology*; D005260:Female; D006801:Humans; D008593:Menopause / Q000187:drug effects*; D008755:Methylergonovine / Q000008:administration & dosage*; D008875:Middle Aged; D009566:Nitrates / Q000008:administration & dosage; D016896:Treatment Outcome; D014661:Vasoconstriction / Q000187:drug effects*; D014664:Vasodilation / Q000187:drug effects
chemical_list: D009566:Nitrates; D004958:Estradiol; D008755:Methylergonovine